Sen. Baucus Still Has Ambitious Agenda: Tax Reform, Deficit Reduction, ACA
Finance Committee chairman decides not to seek re-election in 2014. He has a history of working productively with the drug industry on major legislation such as health reform, the Medicare Modernization Act and PDUFA reauthorizations.
You may also be interested in...
Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.
PhRMA's commitment to contribute $80 billion toward health systems savings over the next 10 years looks like an important tactical win for the brand name industry entering the critical phase of the health reform debate
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.